

2025 OTA Specialty Day In Collaboration with the Pediatric Orthopaedic Society of North America (POSNA)

Friday, March 14, 2025 San Diego, California San Diego Convention Center, Room 29ABCD

## **Planning Committee:**

OTA: Arun Aneja, MD, PhD, Leah Gitajn, MD

POSNA: Philip McClure, MD, Benjamin Scheffer, MD

	8:00 a.m. – 8:05 a.m.	Welcome:
		Emil Schemitsch, MD, FIOTA, OTA Past President
		Todd Milbrandt, MD, POSNA President
<b>POSNA</b>	8:05 a.m. – 8:40 a.m.	Session I:
Symposia	30 Minutes	Adolescent Fractures
Session:		Moderators: Gleeson Rebello, MD, Alex Kuzma, MD
	8:05 a.m 8:15 a.m.	Can I Nail It? - Tibial Shaft Fractures
		- Benjamin Sheffer, MD
	8:15 a.m 8:25 a.m.	Can I Nail It? - Femoral Shaft Retrograde/Anterograde
		Fractures
		- David Lazarus, MD
	8:25 a.m 8:35 a.m.	Adolescent Clavicle Fractures
		- Norman Ward, MD
	8:35 a.m 8:40 a.m.	Discussion and Q&A
	8:40 a.m. – 9:15 a.m.	Session II:
	30 Minutes	PEDS Emergencies: Updates, Tips and Tricks From the
		Pedi-Pods Pedi-Pods
	0.40	Moderators: Vishwas Talwalkar, MD Ashley Levak, MD
	8:40 a.m 8:50 a.m.	Type III Supracondylar Humerus Fractures: Evidence Based
		Update
		- Hilda Kriel, MD
	8:50 a.m 9:00 a.m.	Septic Arthritis in Pediatric Patients
		- Ben Shore, MD
	9:00 a.m 9:10 a.m.	Compartment Syndrome
		- Joshua Abzug, MD
	9:10 a.m 9:15 a.m.	Discussion and Q&A
	9:15 a.m. – 9:45 a.m.	Session III:
	30 Minutes	Pedi Pelvis & Acetabular Fractures
		Moderators: Philip McClure, MD, John Scolaro, MD
	9:15 a.m 9:25 a.m.	Avulsion Fractures of the Pediatric Pelvis: When to Fix?
		- Emmanouil Grigoriou, MD
	9:25 a.m 9:35 a.m.	Tips and Tricks with Pediatric/Adolescent Acetabular
		Fractures

		- Abby Howenstein, MD
	9:35 a.m 9:45 a.m.	Import Talent or Export the Case? Choosing Where to
		Address Pediatric Acetabular Fractures
		- Jessica McGraw-Heinrich, MD
	10.00 10.05	
	10:00 a.m 10:05 a.m. 10:05 a.m 10:20 a.m.	Discussion and Q&A Break
TD.		
Trauma Only Topics	10:20 a.m. – 11:20 a.m. 1 hour	Session IV: Practice Changing Papers You Might Not Have Heard Of
•		Moderators: Lucas Marchand, MD, Holly Pilson, MD
	10:20 a.m 10:30 a.m.	Open vs. Closed Reduction for Young Femoral Neck Fractures
		- Saam Morshed, MD, PhD
	10:30 a.m 10:40 a.m.	Risk-Stratified Thromboprophylaxis Effects of Aspirin Versus Low-Molecular-Weight Heparin in Orthopaedic Trauma Patients
	10.40 a.m. 10.50 a.m.	- Nathan O'Hara, PhD, MHA  Dual Plate Fixation of Distal Femur Fractures
	10:40 a.m 10:50 a.m.	- Eben Carrol, MD
	10:50 a.m 11:00 a.m.	Determining Stability in Posterior Wall Acetabular Fractures
		- Reza Firoozabadi, MD
	11:00 a.m 11:10 a.m.	Thromboelastography (TEG) in Patients With Hip Fractures - Prism Schneider, MD, PhD
	11:10 a.m 11:20 p.m.	Discussion and Q&A
	11:20 a.m. – 12:20 p.m.	Session V:
	1 hour	Orthopaedic Trauma Advances in the "Pipeline" Moderators: Robert O'Toole, MD Taylor Yong, MD
	11:20 a.m 11:30 a.m.	Osseointegration - Kyle Potter, MD
	11:30 a.m 11:40 a.m.	Next Generation Sequencing and Infection Biomarkers - Roman Natoli, MD, PhD
	11:40 a.m 11:50 a.m.	3D Printed Implants - Arjun Srinath, MD
	11:50 a.m 12:00 p.m.	Biphasic Plates - Mark Lee, MD
	12:00 p.m 12:10 p.m.	New Technology in Compartment Syndrome - Andrew Schmidt, MD, FIOTA
	12:10 p.m 12:20 p.m.	Discussion and Q&A
	12:20 p.m 12:35 p.m.	Break
	12:35 p.m 1:35 p.m.	OTA Business Meeting (OTA Members Only)
	1:35 p.m. – 2:45 p.m.	Session VI:
	1 hour, 10 min	OTA Chair's Choice Papers Selected from the 2024 Annual Meeting
	1:35 p.m 1:41 p.m.	Moderators: Nirmal Tejwani, MD Brianna Fram, MD A Randomized Controlled Trial of Locked Plating Versus
		Retrograde Nailing for Periprosthetic Distal Femur Fractures - Aaron Nauth, MD
	1:41 p.m 1:47 p.m.	The HUmeral Shaft Fracture FIXation (HU-FIX) Study: A
		Prospective Randomized Trial of Operative Versus Nonoperative Management of Fractures of the Humeral Diaphysis

1:47 p.m 1:53 p.m.	Tip-Apex Distance (TAD) <10 mm and Apex-to-Center <4 mm as a Risk Factor for Cut-Throughs in Intertrochanteric
	Hip Fracture Fixation
1.52	- Arielle Levine, MS
1:53 p.m 1:59 p.m.	Early Versus Delayed Weightbearing Following
	Operatively Treated Ankle Fracture (WAX): A Randomized
	Controlled Trial and Health Economic Evaluation
1.50	- Christopher Bretherton, BMBS, PhD
1:59 p.m 2:05 p.m.	Comparison of Patellofemoral Chondromalacia Between the
	Suprapatellar and Infrapatellar Techniques of Tibial Nailing
	- Samarth Mittal, MD
2:05 p.m 2:10 p.m.	Discussion and Q&A
2:10 p.m 2:20 p.m.	Resident Memorial Award:
	It Is Feasible and Effective to Deliver Brief Mindfulness
	Training Recordings to Orthopaedic Trauma Patients:
	Results From a Pilot RCT
	- Luke Myhre, MD
2:20 p.m 2:30 p.m.	Bovill Award
2:20 p.m 2:30 p.m.	Introduction:
2:20 p.m 2:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President
2:20 p.m 2:30 p.m.	Introduction:
2:20 p.m 2:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President
2:20 p.m 2:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President Is Aspirin an Effective Thromboprophylaxis in High-Risk
2:20 p.m 2:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the
2:20 p.m 2:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study
2:20 p.m 2:30 p.m. 2:30 p.m 2:45 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the
	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII:
2:30 p.m 2:45 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A
2:30 p.m 2:45 p.m. 2:45 p.m 3:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII:
2:30 p.m 2:45 p.m. 2:45 p.m 3:30 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII: Future OTA Presidents - Where is the OTA Headed?
2:30 p.m 2:45 p.m. 2:45 p.m 3:30 p.m. 45 min	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII: Future OTA Presidents - Where is the OTA Headed? Moderators: Arun Aneja, MD, PhD, Leah Gitajn, MD  Doug Lundy, MD, FIOTA Thomas Higgins, MD
2:30 p.m 2:45 p.m. 2:45 p.m 3:30 p.m. 45 min 2:45 p.m 2:55 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII: Future OTA Presidents - Where is the OTA Headed? Moderators: Arun Aneja, MD, PhD, Leah Gitajn, MD  Doug Lundy, MD, FIOTA
2:30 p.m 2:45 p.m.  2:45 p.m 3:30 p.m. 45 min  2:45 p.m 2:55 p.m. 2:55 p.m 3:05 p.m.	Introduction: Emil Schemitsch, MD, FIOTA, OTA Past President Douglas Lundy, MD, FIOTA OTA President  Is Aspirin an Effective Thromboprophylaxis in High-Risk Patients? A Comprehensive Subpopulation Analysis of the PREVENT CLOT Study - Sandip Tarpada, MD  Discussion and Q&A  Session VII: Future OTA Presidents - Where is the OTA Headed? Moderators: Arun Aneja, MD, PhD, Leah Gitajn, MD  Doug Lundy, MD, FIOTA Thomas Higgins, MD